Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 18/20 | 0.85 |
| ▸ | MEN1 | O00255 | 6/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.85 |
| ▸ | CASP1 | P29466 | 3/20 | 0.85 |
| ▸ | CASP7 | P55210 | 3/20 | 0.85 |
| ▸ | HBB | P68871 | 3/20 | 0.85 |
| ▸ | MAPT | P10636 | 3/20 | 0.85 |
| ▸ | USP2 | O75604 | 2/20 | 0.85 |
| ▸ | LMNA | P02545 | 2/20 | 0.85 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.85 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.85 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.85 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.85 |
| ▸ | TOP2A | P11388 | 1/20 | 0.85 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.85 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27477913 | 1.00 | TOP1 (0.85) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL27781717 | 0.94 | TOP1 (0.84) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL2423989 | 0.94 | TOP1 (0.84) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL4289849 | 0.93 | TOP1 (0.82) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL3377674 | 0.93 | TOP1 (0.82) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL30884751 | 0.93 | TOP1 (0.82) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL23432496 | 0.93 | TOP1 (0.81) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL27504832 | 0.93 | TOP1 (0.81) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL27595325 | 0.93 | TOP1 (0.81) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL5531617 | 0.92 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007052308-A2 | GLYCO-PHOSPHORYLATED BIOLOGICALLY ACTIVE AGENTS | BRAIN N' BEYOND BIOTECH PVT. LTD. (IN) | 2007-05-10 | — | — | WO | claimed |
| CN-1159192-A | Substituted camptothecin derivatives and process for their preparation | PHARMACIA & UPJOHN SPA (IT) | 1997-09-10 | — | — | CN | claimed |
| EP-0777670-A1 | SUBSTITUTED CAMPTOTHECIN DERIVATIVES AND PROCESS FOR THEIR PREPARATION | PHARMACIA & UPJOHN S.p.A. (IT) | 1997-06-11 | — | — | EP | claimed |
| WO-1996037496-A1 | SUBSTITUTED CAMPTOTHECIN DERIVATIVES AND PROCESS FOR THEIR PREPARATION | PHARMACIA & UPJOHN S.P.A. (IT) | 1996-11-28 | — | — | WO | claimed |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-9457098-B2 | Asymmetric bifunctional silyl monomers and particles thereof as prodrugs and delivery vehicles for pharmaceutical, chemical and biological agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2016-10-04 | — | — | US | disclosed |
| US-9457098-B2 | Asymmetric bifunctional silyl monomers and particles thereof as prodrugs and delivery vehicles for pharmaceutical, chemical and biological agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150065670-A1 | ASYMMETRIC BIFUNCTIONAL SILYL MONOMERS AND PARTICLES THEREOF AS PRODRUGS AND DELIVERY VEHICLES FOR PHARMACEUTICAL, CHEMICAL AND BIOLOGICAL AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-03-05 | — | — | US | disclosed |
| US-20150065670-A1 | ASYMMETRIC BIFUNCTIONAL SILYL MONOMERS AND PARTICLES THEREOF AS PRODRUGS AND DELIVERY VEHICLES FOR PHARMACEUTICAL, CHEMICAL AND BIOLOGICAL AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-03-05 | — | — | US | disclosed |
| EP-1995249-B1 | CAMPTOTHECIN DERIVATIVES AND THEIR USE | SHANGHAI INST MATERIA MEDICA (CN) | 2010-11-10 | — | — | EP | disclosed |
| US-20090325996-A1 | CAMPTOTHECIN DERIVATIVES AND THEIR USE | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2009-12-31 | — | — | US | disclosed |
| EP-1995249-A1 | CAMPTOTHECIN DERIVATIVES AND THEIR USE | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2008-11-26 | — | — | EP | disclosed |
| US-5856333-A | ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-01-05 | — | — | US | disclosed |
| CN-1159192-A | Substituted camptothecin derivatives and process for their preparation | PHARMACIA & UPJOHN SPA (IT) | 1997-09-10 | — | — | CN | disclosed |
| EP-0777670-A1 | SUBSTITUTED CAMPTOTHECIN DERIVATIVES AND PROCESS FOR THEIR PREPARATION | PHARMACIA & UPJOHN S.p.A. (IT) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996037496-A1 | SUBSTITUTED CAMPTOTHECIN DERIVATIVES AND PROCESS FOR THEIR PREPARATION | PHARMACIA & UPJOHN S.P.A. (IT) | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | TOP1 531/4885MEN1 2250/4885KMT2A 2014/4885 |
| US-20150065670-A1 | ASYMMETRIC BIFUNCTIONAL SILYL MONOMERS AND PARTICLES THEREOF AS PRODRUGS AND DELIVERY VEHICLES FOR PHARMACEUTICAL, CHEMICAL AND BIOLOGICAL AGENTS | PAICS, BSG, ILK | TOP1 3788/4885MEN1 1428/4885KMT2A 3412/4885 |
| US-20090325996-A1 | CAMPTOTHECIN DERIVATIVES AND THEIR USE | TOP2A, TOP1, TOP2B | TOP1 2/4885MEN1 599/4885KMT2A 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.